Tahseen Mozaffar

13.0k total citations · 1 hit paper
165 papers, 4.1k citations indexed

About

Tahseen Mozaffar is a scholar working on Neurology, Molecular Biology and Epidemiology. According to data from OpenAlex, Tahseen Mozaffar has authored 165 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Neurology, 39 papers in Molecular Biology and 38 papers in Epidemiology. Recurrent topics in Tahseen Mozaffar's work include Inflammatory Myopathies and Dermatomyositis (33 papers), Lysosomal Storage Disorders Research (29 papers) and Neurogenetic and Muscular Disorders Research (25 papers). Tahseen Mozaffar is often cited by papers focused on Inflammatory Myopathies and Dermatomyositis (33 papers), Lysosomal Storage Disorders Research (29 papers) and Neurogenetic and Muscular Disorders Research (25 papers). Tahseen Mozaffar collaborates with scholars based in United States, United Kingdom and Germany. Tahseen Mozaffar's co-authors include Namita Goyal, Alan Pestronk, Ranjan Gupta, Andrew R. Findlay, Virginia Kimonis, Hiroshi Mitsumoto, Rup Tandan, Dan H. Moore, Richard J. Barohn and Robert G. Miller and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Blood.

In The Last Decade

Tahseen Mozaffar

153 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

224th ENMC International Workshop:

2017 356 citations Yves Allenbach, Andrew L. Mammen et al. Neuromuscular Disorders profile →

Peers

Countries citing papers authored by Tahseen Mozaffar

Since Specialization

Citations

This map shows the geographic impact of Tahseen Mozaffar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tahseen Mozaffar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tahseen Mozaffar more than expected).

Fields of papers citing papers by Tahseen Mozaffar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tahseen Mozaffar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tahseen Mozaffar. The network helps show where Tahseen Mozaffar may publish in the future.

Co-authorship network of co-authors of Tahseen Mozaffar

This figure shows the co-authorship network connecting the top 25 collaborators of Tahseen Mozaffar. A scholar is included among the top collaborators of Tahseen Mozaffar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tahseen Mozaffar. Tahseen Mozaffar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis 2025 ·Annals of Clinical and Translational Neurology ·Nizar Chahin, (unknown), (unknown), Charles A. Stewart, Christopher M. Jewell, Metin Kurtoğlu, Miloš D. Miljković, Tuan Vu, Tahseen Mozaffar, James F. Howard, (unknown)	0
2	Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease 2024 ·Journal of Patient-Reported Outcomes ·Priya S. Kishnani, Barry J. Byrne, Kristl G. Claeys, Jordi Díaz‐Manera, Mazen M. Dimachkie, Hani Kushlaf, Tahseen Mozaffar, Mark Roberts, Benedikt Schoser, Noemi Hummel, (unknown), Fred Holdbrook, Simon Shohet, António Toscano, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
3	The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms 2024 ·The Journal of Rheumatology ·Lisa Christopher‐Stine, (unknown), Hector Chinoy, Namita Goyal, (unknown), David Isenberg, (unknown), Ingrid E. Lundberg, Tahseen Mozaffar, Sanjay N. Rakhade, (unknown), Rohit Aggarwal	1
4	Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial 2024 ·Molecular Therapy ·(unknown), (unknown), Tahseen Mozaffar, Jason Stadanlick, (unknown), (unknown), Alexandra G. Ellis, Jazmean K. Williams, (unknown), Quynh Lam, (unknown), (unknown), (unknown), (unknown), Claire Miller, (unknown), David Chang, Samik Basu	17
5	Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials 2024 ·Molecular Genetics and Metabolism Reports ·Tahseen Mozaffar, Lionel Riou França, Jérôme Msihid, Pragya Shukla, Irina Proskorovsky, Tianyue Zhou, Magali Periquet, Kristina An Haack, (unknown), Volker Straub	1
6	Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease 2024 ·Frontiers in Neurology ·Barry J. Byrne, Giancarlo Parenti, Benedikt Schoser, Ans T. van der Ploeg, Hung Do, Brian W. Fox, Mitchell Goldman, Franklin K. Johnson, (unknown), Nickita Mehta, John Mondick, M. Osman Sheikh, (unknown), Steven Tuske, (unknown), Jill M. Weimer, Tahseen Mozaffar	6
7	Effects of enzyme replacement therapy on bone density in late onset Pompe disease 2023 ·Molecular Genetics and Metabolism ·(unknown), Angela Martin, (unknown), Tahseen Mozaffar, Virginia Kimonis	3
8	Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02) 2023 ·Journal of Neurology ·Barry J. Byrne, Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic, Paula R. Clemens, Özlem Göker-Alpan, Xue Ming, Mark S. Roberts, Matthias Vorgerd, Kumaraswamy Sivakumar, Ans T. van der Ploeg, Mitchell Goldman, (unknown), Fred Holdbrook, (unknown), Elfrida R. Benjamin, Franklin K. Johnson, (unknown), Yasmine Wasfi, Tahseen Mozaffar	14
9	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis 2022 ·Science Translational Medicine ·Kyla A. Britson, Jonathan P. Ling, Kerstin E. Braunstein, Janelle M. Montagne, Jenna M. Kastenschmidt, Andrew D. Wilson, Chiseko Ikenaga, William Tsao, Iago Pinal‐Fernandez, K. Russell, Nicole Reed, Tahseen Mozaffar, Kathryn R. Wagner, Lyle W. Ostrow, Andrea M. Corse, Andrew L. Mammen, S. Armando Villalta, H. Benjamin Larman, Philip C. Wong, Thomas E. Lloyd	34
10	Correlations of disease severity outcome measures in inclusion body myositis 2022 ·Neuromuscular Disorders ·Namita Goyal, Steven A. Greenberg, (unknown), (unknown), Vivian Li, Marie Wencel, (unknown), Leo H. Wang, Anton M. Palma, S. Armando Villalta, Tahseen Mozaffar	6
11	Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices 2021 ·Neurology Genetics ·Marie Wencel, Aziz Shaibani, Namita Goyal, Mazen M. Dimachkie, Jaya Trivedi, Nicholas E. Johnson, Laurie Gutmann, Matthew Wicklund, (unknown), Angela Genge, Miriam Freimer, Neelam Goyal, Alan Pestronk, Julaine Florence, Chafic Karam, Jeffrey Ralph, (unknown), (unknown), Steve Hopkins, Tahseen Mozaffar	5
12	Dysphagia in Inclusion Body Myositis, A Disease of the Elderly 2021 ·Namita Goyal, Tahseen Mozaffar	4
13	Adult MTM1 -related myopathy carriers 2019 ·Neurology ·Ben Cocanougher, (unknown), (unknown), Minal Jain, M. Waite, (unknown), Jason D. Wittenbach, (unknown), (unknown), A. Micheil Innes, (unknown), Tahseen Mozaffar, Andrew E. Arai, Sandra Donkervoort, Carsten G. Bönnemann, A. Reghan Foley	16
14	SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain 2019 ·Journal of Medical Genetics ·Richard J.L.F. Lemmers, Nienke van der Stoep, Patrick J. van der Vliet, Steven A. Moore, David San León, Katherine Johnson, Ana Töpf, Volker Straub, Teresinha Evangelista, Tahseen Mozaffar, Virginia Kimonis, Natalie D. Shaw, Rita Selvatici, Alessandra Ferlini, Nicol C. Voermans, Baziel G.M. van Engelen, Sabrina Sacconi, Rabi Tawil, Meindert H. Lamers, Silvère M. van der Maarel	23
15	A Case of Pembrolizumab-Induced Autoimmune Necrotizing Myopathy (P3.4-004) 2019 ·Neurology ·(unknown), (unknown), Mari Perez‐Rosendahl, Tahseen Mozaffar	0
16	224th ENMC International Workshop: breakdown → 2017 ·Neuromuscular Disorders ·Yves Allenbach, Andrew L. Mammen, Olivier Benvéniste, Werner Stenzel, Anthony A. Amato, (unknown), Jan De Bleecker, Ingrid de Groot, Marjolein Visser, Hans H. Goebel, B. Hervier, (unknown), David Hilton‐Jones, Janine A. Lamb, Ingrid E. Lundberg, Tahseen Mozaffar, Ichizo Nishino, Alan Pestronk, Ulrike Schara, (unknown)	356
17	The Homozygote VCPR155H/R155H Mouse Model Exhibits Accelerated Human VCP-Associated Disease Pathology 2012 ·PLoS ONE ·Angèle Nalbandian, Katrina J. Llewellyn, Masashi Kitazawa, Hong Yin, Mallikarjun Badadani, Négar Khanlou, Robert A. Edwards, Christopher Nguyen, Jogeshwar Mukherjee, Tahseen Mozaffar, Giles Watts, John H. Weiss, Virginia Kimonis	52
18	Compressive Neuropathies of the Upper Extremity: Update on Pathophysiology, Classification, and Electrodiagnostic Findings 2010 ·The Journal Of Hand Surgery ·Minal Tapadia, Tahseen Mozaffar, Ranjan Gupta	74
19	PIP(2) binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome 2003 ·HAL (Le Centre pour la Communication Scientifique Directe) ·Michael Donaldson, Jeffrey L. Jensen, Martin Tristani‐Firouzi, Rabi Tawil, Saı̈d Bendahhou, (unknown), Ana María Cobo, Juan José Poza, Elijah R. Behr, John Wagstaff, Pierre Szepetowski, Sandrine Pereira, Tahseen Mozaffar, Diana M. Escolar, Ying‐Hui Fu, Louis J. Ptáček	1
20	Critical illness myopathy 2001 ·Muscle & Nerve ·Tahseen Mozaffar	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact